Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 6/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974489 | 0.93 | HPGD (0.36) | GPR35HDAC4PTPN1HDAC8HPGD | |
| SCHEMBL3969532 | 0.91 | HDAC4 (0.40) | GPR35HDAC4PTPN1HDAC8HPGD | |
| SCHEMBL3968958 | 0.90 | HPGD (0.43) | GPR35HDAC4PTPN1HPGDAKR1B1 | |
| SCHEMBL6245263 | 0.90 | PPARG (0.35) | GPR35HDAC4PTPN1HDAC8HPGD | |
| SCHEMBL3964968 | 0.88 | AKR1B1 (0.39) | GPR35HDAC4PTPN1HDAC8HPGD | |
| SCHEMBL6246085 | 0.86 | HPGD (0.40) | GPR35HDAC4PTPN1HPGDAKR1B1 | |
| SCHEMBL3966370 | 0.85 | HDAC4 (0.39) | GPR35HDAC4PTPN1HDAC8HPGD | |
| SCHEMBL3968162 | 0.84 | ESRRA (0.38) | HDAC4PTPN1HDAC8HPGDPPARG | |
| SCHEMBL6246069 | 0.84 | PPARG (0.32) | HDAC4HPGDPPARG | |
| SCHEMBL3966279 | 0.83 | FFAR1 (0.40) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087576-B2 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | claimed |
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
| US-7087576-B2 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2005034981-A1 | DIPEPTIDE PHENYL ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | BEXEL PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075293-A1 | Antidiabetic agents; anticholesterol agents; obesity; antiinflammatory agents; autoimmune disease; multiple sclerosis; antiarthritic agents | DPP4, GPR119, IAPP | GPR35 825/4885HDAC4 324/4885PTPN1 818/4885 |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | FFAR4, IAPP, FFAR2 | GPR35 376/4885HDAC4 904/4885PTPN1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.